<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03425097</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-44650</org_study_id>
    <nct_id>NCT03425097</nct_id>
  </id_info>
  <brief_title>Fexofenadine Use in Gastroesophageal Reflux Symptoms</brief_title>
  <official_title>A Randomized, Double Blind, Crossover Trial Comparing Fexofenadine to Placebo for the Treatment of Proton Pump Inhibitor Refractory Gastroesophageal Reflux Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators wish to study the effectiveness of Fexofenadine (an over the counter&#xD;
      allergy pill) for the treatment of gastroesophageal reflux symptoms in patients who still&#xD;
      have symptoms despite being on a proton pump inhibitor. The investigators will do this by&#xD;
      giving participants both Fexofenadine (an H1 blocker) for 2 weeks and placebo (sugar pill)&#xD;
      for 2 weeks. The participants will not know which drug they are getting at a particular time.&#xD;
      This will help the investigators better assess the true effectiveness of Fexofenadine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Around 18-28% of North American adults have gastroesophageal reflux symptoms once per week.&#xD;
      Of those patients up to 60% may have an inadequate response to proton pump inhibitors and&#xD;
      have persistent symptoms. One possible explanation is that this group of patients has nerve&#xD;
      related pain. It is thought that H1 receptor activation may sensitize the gastrointestinal&#xD;
      tract and esophagus to pain. H1 blockers such as anti-histamines may play a role in treatment&#xD;
      of gastroesophageal reflux symptoms that are refractory to proton pump inhibitors by reducing&#xD;
      pain perception. The investigators wish to conduct a randomized control trial to test this&#xD;
      hypothesis. The investigators will do this by giving participants both Fexofenadine (an H1&#xD;
      blocker) for 2 weeks and placebo (sugar pill) for 2 weeks. The participants will not know&#xD;
      which drug they are getting at a particular time. This will help the investigators better&#xD;
      assess the true effectiveness of Fexofenadine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated due to insufficient evidence for Fexofenadine efficacy to treat GERD&#xD;
    symptoms after the interim analysis.&#xD;
  </why_stopped>
  <start_date type="Actual">February 7, 2018</start_date>
  <completion_date type="Actual">January 8, 2019</completion_date>
  <primary_completion_date type="Actual">January 8, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percent of Days With Reflux</measure>
    <time_frame>2 weeks per treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Number of Reflux Episodes Per Day</measure>
    <time_frame>2 weeks per treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean GERD-HRQL Questionnaire Score</measure>
    <time_frame>2 weeks per treatment</time_frame>
    <description>The questionnaire consists of 10 questions with responses of 0-5. The responses of the 10 questions are totaled (range of 0-50) where a higher total indicates more severe disease than a lower total.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Symptom Severity Score</measure>
    <time_frame>2 weeks per treatment</time_frame>
    <description>Severity of reflux symptoms on a scale of 0-4 (0=none, 1=mild, 2=moderate, 3=severe, 4=very severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Rescue Medications Per Day</measure>
    <time_frame>2 weeks per treatment</time_frame>
    <description>Medications such as Tums or Pepcid can be used if reflux symptoms are severe and relief is needed (additional doses of proton pump inhibitors are not allowed beyond the regular dosing)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Medication Preference</measure>
    <time_frame>Will be assessed at the end of the trial (total trial time is 6 weeks)</time_frame>
    <description>Patients will be asked which medication they think better helps treat their reflux symptoms, placebo or Fexofenadine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Participants With Side Effects</measure>
    <time_frame>Will be assessed at the end of the initial treatment period (2 weeks) and at the end of the crossover period (2 weeks)</time_frame>
    <description>Patients will write down side effects at the end of each treatment period. If severe patients should seek medical attention immediately and report the side effects to us.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Gastroesophageal Reflux</condition>
  <arm_group>
    <arm_group_label>Fexofenadine then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will get 2 weeks of fexofenadine, then 1 week of nothing, then 2 weeks of placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then Fexofenadine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will get 2 weeks of placebo, then 1 week of nothing, then 2 weeks of fexofenadine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fexofenadine</intervention_name>
    <description>Fexofenadine 180 mg in the morning</description>
    <arm_group_label>Fexofenadine then Placebo</arm_group_label>
    <arm_group_label>Placebo then Fexofenadine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - Cap</intervention_name>
    <description>Placebo cap in the morning</description>
    <arm_group_label>Fexofenadine then Placebo</arm_group_label>
    <arm_group_label>Placebo then Fexofenadine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A minimum 6-month history of heartburn and regurgitation, as their main symptom&#xD;
&#xD;
          -  Experience at least 3-4 days with episodes of heartburn or regurgitation per week&#xD;
&#xD;
          -  Female patients who are postmenopausal or using acceptable methods of birth control.&#xD;
&#xD;
        Exclusion Criteria (selected)&#xD;
&#xD;
          -  Esophageal stricture&#xD;
&#xD;
          -  Primary esophageal motility disorder&#xD;
&#xD;
          -  Systemic sclerosis&#xD;
&#xD;
          -  Active inflammatory bowel disease&#xD;
&#xD;
          -  Zollinger-Ellison syndrome&#xD;
&#xD;
          -  Active gastric or duodenal ulcer&#xD;
&#xD;
          -  Active infectious or inflammatory conditions of the small or large intestine&#xD;
&#xD;
          -  Malabsorption syndromes of the intestine&#xD;
&#xD;
          -  History of gastrointestinal cancer&#xD;
&#xD;
          -  Current active cancer&#xD;
&#xD;
          -  Prior gastric or intestinal surgery&#xD;
&#xD;
          -  Pregnant or breast feeding&#xD;
&#xD;
          -  Other serious psychiatric or medical disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford Health Care</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 25, 2018</study_first_submitted>
  <study_first_submitted_qc>February 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2018</study_first_posted>
  <results_first_submitted>January 27, 2021</results_first_submitted>
  <results_first_submitted_qc>January 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 17, 2021</results_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Thomas Zikos</investigator_full_name>
    <investigator_title>Fellow in Gastroenterology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Esophagitis, Peptic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fexofenadine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT03425097/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants entered a 7 day run in period prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fexofenadine Then Placebo</title>
          <description>Patients in this group will get 2 weeks of fexofenadine (180 mg), then 1 week of nothing, then 2 weeks of placebo.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Then Fexofenadine</title>
          <description>Patients in this group will get 2 weeks of placebo, then 1 week of nothing, then 2 weeks of fexofenadine (180 mg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1 (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period (1 Week)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Treatment Period (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Patients in this group will get 2 weeks of fexofenadine (180 mg) or matching placebo, then 1 week of nothing, then 2 weeks of the opposite treatment.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <population>Age data are available for only 6 participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>40-49 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-59 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-79 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80-89 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Sex data are available for only 9 participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>Ethnicity data are available for only 9 participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent of Days With Reflux</title>
        <time_frame>2 weeks per treatment</time_frame>
        <population>Participants with available data are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Run-in Period</title>
            <description>Participants entered a 1 week run-in period prior to randomization.</description>
          </group>
          <group group_id="O2">
            <title>Fexofenadine</title>
            <description>Fexofenadine (180 mg) for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Fexofenadine placebo for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent of Days With Reflux</title>
          <population>Participants with available data are included in the analysis.</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.4" lower_limit="59.4" upper_limit="107.4"/>
                    <measurement group_id="O2" value="52.4" lower_limit="4.3" upper_limit="100.4"/>
                    <measurement group_id="O3" value="52.4" lower_limit="12.5" upper_limit="92.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Number of Reflux Episodes Per Day</title>
        <time_frame>2 weeks per treatment</time_frame>
        <population>Participants with available data are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Run-in Period</title>
            <description>Participants entered a 1 week run-in period prior to randomization.</description>
          </group>
          <group group_id="O2">
            <title>Fexofenadine</title>
            <description>Fexofenadine (180 mg) for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Fexofenadine placebo for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Reflux Episodes Per Day</title>
          <population>Participants with available data are included in the analysis</population>
          <units>episodes</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" lower_limit="0.73" upper_limit="2.75"/>
                    <measurement group_id="O2" value="0.69" lower_limit="-0.01" upper_limit="1.40"/>
                    <measurement group_id="O3" value="0.67" lower_limit="-0.05" upper_limit="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean GERD-HRQL Questionnaire Score</title>
        <description>The questionnaire consists of 10 questions with responses of 0-5. The responses of the 10 questions are totaled (range of 0-50) where a higher total indicates more severe disease than a lower total.</description>
        <time_frame>2 weeks per treatment</time_frame>
        <population>Participants with available data are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Run-in Period</title>
            <description>Participants entered a 1 week run-in period prior to randomization.</description>
          </group>
          <group group_id="O2">
            <title>Fexofenadine</title>
            <description>Fexofenadine (180 mg) for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Fexofenadine placebo for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean GERD-HRQL Questionnaire Score</title>
          <description>The questionnaire consists of 10 questions with responses of 0-5. The responses of the 10 questions are totaled (range of 0-50) where a higher total indicates more severe disease than a lower total.</description>
          <population>Participants with available data are included in the analysis</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" lower_limit="2.5" upper_limit="29.8"/>
                    <measurement group_id="O2" value="9.8" lower_limit="-1.5" upper_limit="21.2"/>
                    <measurement group_id="O3" value="12.3" lower_limit="4.0" upper_limit="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Symptom Severity Score</title>
        <description>Severity of reflux symptoms on a scale of 0-4 (0=none, 1=mild, 2=moderate, 3=severe, 4=very severe)</description>
        <time_frame>2 weeks per treatment</time_frame>
        <population>Participants with available data are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Run-in Period</title>
            <description>Participants entered a 1 week run-in period prior to randomization.</description>
          </group>
          <group group_id="O2">
            <title>Fexofenadine</title>
            <description>Fexofenadine (180 mg) for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Fexofenadine placebo for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Symptom Severity Score</title>
          <description>Severity of reflux symptoms on a scale of 0-4 (0=none, 1=mild, 2=moderate, 3=severe, 4=very severe)</description>
          <population>Participants with available data are included in the analysis</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.6" upper_limit="1.9"/>
                    <measurement group_id="O2" value="0.8" lower_limit="-0.03" upper_limit="1.5"/>
                    <measurement group_id="O3" value="0.7" lower_limit="-0.02" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Rescue Medications Per Day</title>
        <description>Medications such as Tums or Pepcid can be used if reflux symptoms are severe and relief is needed (additional doses of proton pump inhibitors are not allowed beyond the regular dosing)</description>
        <time_frame>2 weeks per treatment</time_frame>
        <population>Participants with available data are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Run-in Period</title>
            <description>Participants entered a 1 week run-in period prior to randomization.</description>
          </group>
          <group group_id="O2">
            <title>Fexofenadine</title>
            <description>Fexofenadine (180 mg) for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Fexofenadine placebo for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Rescue Medications Per Day</title>
          <description>Medications such as Tums or Pepcid can be used if reflux symptoms are severe and relief is needed (additional doses of proton pump inhibitors are not allowed beyond the regular dosing)</description>
          <population>Participants with available data are included in the analysis</population>
          <units>medications</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" lower_limit="-0.31" upper_limit="0.89"/>
                    <measurement group_id="O2" value="0.52" lower_limit="-0.75" upper_limit="1.80"/>
                    <measurement group_id="O3" value="0.17" lower_limit="-0.14" upper_limit="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Medication Preference</title>
        <description>Patients will be asked which medication they think better helps treat their reflux symptoms, placebo or Fexofenadine.</description>
        <time_frame>Will be assessed at the end of the trial (total trial time is 6 weeks)</time_frame>
        <population>Data were not collected for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Run-in Period</title>
            <description>Participants entered a 1 week run-in period prior to randomization.</description>
          </group>
          <group group_id="O2">
            <title>Fexofenadine</title>
            <description>Fexofenadine (180 mg) for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Fexofenadine placebo for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Medication Preference</title>
          <description>Patients will be asked which medication they think better helps treat their reflux symptoms, placebo or Fexofenadine.</description>
          <population>Data were not collected for this outcome measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants With Side Effects</title>
        <description>Patients will write down side effects at the end of each treatment period. If severe patients should seek medical attention immediately and report the side effects to us.</description>
        <time_frame>Will be assessed at the end of the initial treatment period (2 weeks) and at the end of the crossover period (2 weeks)</time_frame>
        <population>Participants with available data are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Fexofenadine</title>
            <description>Fexofenadine (180 mg) for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Fexofenadine placebo for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants With Side Effects</title>
          <description>Patients will write down side effects at the end of each treatment period. If severe patients should seek medical attention immediately and report the side effects to us.</description>
          <population>Participants with available data are included in the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fexofenadine</title>
          <description>Fexofenadine (180 mg) for 2 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Fexofenadine placebo for 2 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nosebleed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was underpowered as it did not meet its planned sample size of 40 participants.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Thomas A Zikos, MD</name_or_title>
      <organization>Stanford University</organization>
      <phone>(408) 426-5599</phone>
      <email>zikosta@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

